Autotrasplante (AT) de progenitores hematopoyéticos en mieloma múltiple: Experiencia clínica

Background:Multiple myeloma is rarely curable. Advances in high dose chemotherapy and stem cell transplantation have improved overall survival and event-free disease periods, but relapses are inevitable. Aim: To report our experience with AT in multiple myeloma, between 1994 and 2003. Material and M...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Flores P,Claudio, Conte L,Guillermo, Fardella B,Patricia, Araos H,Daniel, Alfaro L,Jorge, Aravena R,Paola, González G,Néstor, Larrondo L,Milton
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2005
Materias:	Hematopoietic stem cells Melphalan Multiple myeloma
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872005000800004
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872005000800004
record_format	dspace
spelling	oai:scielo:S0034-988720050008000042014-08-12Autotrasplante (AT) de progenitores hematopoyéticos en mieloma múltiple: Experiencia clínicaFlores P,ClaudioConte L,GuillermoFardella B,PatriciaAraos H,DanielAlfaro L,JorgeAravena R,PaolaGonzález G,NéstorLarrondo L,Milton Hematopoietic stem cells Melphalan Multiple myeloma Background:Multiple myeloma is rarely curable. Advances in high dose chemotherapy and stem cell transplantation have improved overall survival and event-free disease periods, but relapses are inevitable. Aim: To report our experience with AT in multiple myeloma, between 1994 and 2003. Material and Methods: Retrospective analysis of 20 patients (12 women), with a mean age of 51.1 years. VAD (vincristine, doxorubicin and dexamethasone) was used as initial therapy in 19 patients. High dose cyclophosphamide (11 patients) and variations of VAD regimen (7) associated with granulocyte colony stimulating factor were used for peripheral-blood stem cell harvest. The conditioning regimen consisted of melphalan 200 mg/m² followed by the reinfusion of peripheral-blood stem cells 24 hours later. The median number of CD34 cells infused was 3,3x10(6)/kg. Three patients were subjected to a second auto graft and one to a non-myeloablative transplant. Mean follow up was 35.5 months. Results: Mucositis and febrile neutropenia were common complications. The median number of days for neutrophyl engraftment was 9 (range 8-11) and for platelets, 10 (range 7-13). No patient died. Complete remission was obtained in 60% (12/20), progession-free survival was 30 months and overall median survival, 47 months. Conclusions: The AT with high-dose melphalan is a safe procedure in our hospital, without mortality and engraftment in all the patients. Complete remission and progression free survival were similar to those reported abroad but the overall median survival was lowerinfo:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.133 n.8 20052005-08-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872005000800004es10.4067/S0034-98872005000800004
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Hematopoietic stem cells Melphalan Multiple myeloma
spellingShingle	Hematopoietic stem cells Melphalan Multiple myeloma Flores P,Claudio Conte L,Guillermo Fardella B,Patricia Araos H,Daniel Alfaro L,Jorge Aravena R,Paola González G,Néstor Larrondo L,Milton Autotrasplante (AT) de progenitores hematopoyéticos en mieloma múltiple: Experiencia clínica
description	Background:Multiple myeloma is rarely curable. Advances in high dose chemotherapy and stem cell transplantation have improved overall survival and event-free disease periods, but relapses are inevitable. Aim: To report our experience with AT in multiple myeloma, between 1994 and 2003. Material and Methods: Retrospective analysis of 20 patients (12 women), with a mean age of 51.1 years. VAD (vincristine, doxorubicin and dexamethasone) was used as initial therapy in 19 patients. High dose cyclophosphamide (11 patients) and variations of VAD regimen (7) associated with granulocyte colony stimulating factor were used for peripheral-blood stem cell harvest. The conditioning regimen consisted of melphalan 200 mg/m² followed by the reinfusion of peripheral-blood stem cells 24 hours later. The median number of CD34 cells infused was 3,3x10(6)/kg. Three patients were subjected to a second auto graft and one to a non-myeloablative transplant. Mean follow up was 35.5 months. Results: Mucositis and febrile neutropenia were common complications. The median number of days for neutrophyl engraftment was 9 (range 8-11) and for platelets, 10 (range 7-13). No patient died. Complete remission was obtained in 60% (12/20), progession-free survival was 30 months and overall median survival, 47 months. Conclusions: The AT with high-dose melphalan is a safe procedure in our hospital, without mortality and engraftment in all the patients. Complete remission and progression free survival were similar to those reported abroad but the overall median survival was lower
author	Flores P,Claudio Conte L,Guillermo Fardella B,Patricia Araos H,Daniel Alfaro L,Jorge Aravena R,Paola González G,Néstor Larrondo L,Milton
author_facet	Flores P,Claudio Conte L,Guillermo Fardella B,Patricia Araos H,Daniel Alfaro L,Jorge Aravena R,Paola González G,Néstor Larrondo L,Milton
author_sort	Flores P,Claudio
title	Autotrasplante (AT) de progenitores hematopoyéticos en mieloma múltiple: Experiencia clínica
title_short	Autotrasplante (AT) de progenitores hematopoyéticos en mieloma múltiple: Experiencia clínica
title_full	Autotrasplante (AT) de progenitores hematopoyéticos en mieloma múltiple: Experiencia clínica
title_fullStr	Autotrasplante (AT) de progenitores hematopoyéticos en mieloma múltiple: Experiencia clínica
title_full_unstemmed	Autotrasplante (AT) de progenitores hematopoyéticos en mieloma múltiple: Experiencia clínica
title_sort	autotrasplante (at) de progenitores hematopoyéticos en mieloma múltiple: experiencia clínica
publisher	Sociedad Médica de Santiago
publishDate	2005
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872005000800004
work_keys_str_mv	AT florespclaudio autotrasplanteatdeprogenitoreshematopoyeticosenmielomamultipleexperienciaclinica AT contelguillermo autotrasplanteatdeprogenitoreshematopoyeticosenmielomamultipleexperienciaclinica AT fardellabpatricia autotrasplanteatdeprogenitoreshematopoyeticosenmielomamultipleexperienciaclinica AT araoshdaniel autotrasplanteatdeprogenitoreshematopoyeticosenmielomamultipleexperienciaclinica AT alfaroljorge autotrasplanteatdeprogenitoreshematopoyeticosenmielomamultipleexperienciaclinica AT aravenarpaola autotrasplanteatdeprogenitoreshematopoyeticosenmielomamultipleexperienciaclinica AT gonzalezgnestor autotrasplanteatdeprogenitoreshematopoyeticosenmielomamultipleexperienciaclinica AT larrondolmilton autotrasplanteatdeprogenitoreshematopoyeticosenmielomamultipleexperienciaclinica
_version_	1718436217401376768

Autotrasplante (AT) de progenitores hematopoyéticos en mieloma múltiple: Experiencia clínica

Ejemplares similares